{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:07:59Z","timestamp":1754021279485},"reference-count":41,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2024.12622","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T12:34:46Z","timestamp":1719318886000},"source":"Crossref","is-referenced-by-count":3,"title":["Immune myocarditis induced by sintilimab therapy: A case report"],"prefix":"10.3892","volume":"28","author":[{"given":"Yu","family":"Li","sequence":"first","affiliation":[{"name":"Translational Medical Center, Weifang Second People's Hospital, Weifang Respiratory Disease Hospital, Weifang, Shandong 261041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baowei","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Weifang Second People's Hospital, Weifang Respiratory Disease Hospital, Weifang, Shandong 261041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Yang","sequence":"additional","affiliation":[{"name":"Translational Medical Center, Weifang Second People's Hospital, Weifang Respiratory Disease Hospital, Weifang, Shandong 261041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Weifang Second People's Hospital, Weifang Respiratory Disease Hospital, Weifang, Shandong 261041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubing","family":"Wang","sequence":"additional","affiliation":[{"name":"Translational Medical Center, Weifang Second People's Hospital, Weifang Respiratory Disease Hospital, Weifang, Shandong 261041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihua","family":"Qu","sequence":"additional","affiliation":[{"name":"Translational Medical Center, Weifang Second People's Hospital, Weifang Respiratory Disease Hospital, Weifang, Shandong 261041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Tang","sequence":"additional","affiliation":[{"name":"Translational Medical Center, Weifang Second People's Hospital, Weifang Respiratory Disease Hospital, Weifang, Shandong 261041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"115113","key":"key20240726093658_b1-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115113","article-title":"Strategies for developing PD-1 inhibitors and future directions","volume":"202","author":"Chen","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"28","key":"key20240726093658_b2-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"key20240726093658_b3-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2174\/1566524022666220610094716","article-title":"CTLA-4: As an immunosuppressive immune checkpoint in breast cancer","volume":"23","author":"Ghahremani Dehbokri","year":"2023","journal-title":"Curr Mol Med"},{"issue":"779691","key":"key20240726093658_b4-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"issue":"39","key":"key20240726093658_b5-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): Diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"306","key":"key20240726093658_b6-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"10948","key":"key20240726093658_b7-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810948","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: A systematic review","volume":"23","author":"Cozma","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20240726093658_b8-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20240726093658_b9-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0167-5273(89)90274-x","article-title":"Immunosuppressive treatment in myocarditis","volume":"22","author":"Salvi","year":"1989","journal-title":"Int J Cardiol"},{"issue":"851032","key":"key20240726093658_b10-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.851032","article-title":"A systematic review of the mechanisms involved in immune checkpoint inhibitors cardiotoxicity and challenges to improve clinical safety","volume":"10","author":"Rubio-Infante","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"key20240726093658_b11-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJM199706263362603","article-title":"Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter giant cell myocarditis study group investigators","volume":"336","author":"Cooper","year":"1997","journal-title":"N Engl J Med"},{"issue":"e145186","key":"key20240726093658_b12-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: Manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"issue":"91","key":"key20240726093658_b13-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key20240726093658_b14-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: Breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"key20240726093658_b15-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2023.3371","article-title":"Diagnosis and treatment of acute myocarditis: A review","volume":"329","author":"Ammirati","year":"2023","journal-title":"JAMA"},{"key":"key20240726093658_b16-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/14779072.2023.2219895","article-title":"Myocarditis and autoimmunity","volume":"21","author":"Matsumori","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"key20240726093658_b17-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMra0800028","article-title":"Myocarditis","volume":"360","author":"Cooper","year":"2009","journal-title":"N Engl J Med"},{"key":"key20240726093658_b18-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.7861\/clinmed.2021-0121","article-title":"Acute myocarditis: Aetiology, diagnosis and management","volume":"21","author":"Lampejo","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"key20240726093658_b19-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1053\/j.jvca.2019.12.052","article-title":"Viral myocarditis-incidence, diagnosis and management","volume":"34","author":"Olejniczak","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"key20240726093658_b20-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s10875-009-9339-z","article-title":"Myocarditis: Infection versus autoimmunity","volume":"29","author":"Rose","year":"2009","journal-title":"J Clin Immunol"},{"key":"key20240726093658_b21-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S2213-2600(22)00059-5","article-title":"Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: A systematic review and meta-analysis","volume":"10","author":"Ling","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"819790","key":"key20240726093658_b22-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819790","article-title":"Elevated levels of soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and systemic inflammatory stress as potential contributors to immune suppression and generalized tumorigenesis in a cohort of South African xeroderma pigmentosum patients","volume":"12","author":"Kgokolo","year":"2022","journal-title":"Front Oncol"},{"key":"key20240726093658_b23-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.semcancer.2021.08.008","article-title":"Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy","volume":"86","author":"Im","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"938470","key":"key20240726093658_b24-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.938470","article-title":"V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"key20240726093658_b25-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"594558","key":"key20240726093658_b26-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: A promising anti-tumor PD-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"key20240726093658_b27-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"key20240726093658_b28-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8 + T-cell-mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"key20240726093658_b29-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11912-023-01411-7","article-title":"Cardiovascular effects of immune checkpoint inhibitors: More than just myocarditis","volume":"25","author":"Inno","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"key20240726093658_b30-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20240726093658_b31-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"e1361097","key":"key20240726093658_b32-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1361097","article-title":"Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab","volume":"6","author":"Reuben","year":"2017","journal-title":"Oncoimmunology"},{"key":"key20240726093658_b33-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cvr\/cvz025","article-title":"T cell checkpoint regulators in the heart","volume":"115","author":"Grabie","year":"2019","journal-title":"Cardiovasc Res"},{"key":"key20240726093658_b34-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ni.1835","article-title":"CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms","volume":"11","author":"Ise","year":"2010","journal-title":"Nat Immunol"},{"key":"key20240726093658_b35-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1177\/10781552211027339","article-title":"Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"key20240726093658_b36-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"e000247","key":"key20240726093658_b37-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"issue":"2320","key":"key20240726093658_b38-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092320","article-title":"Cancer therapy-related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"e0271483","key":"key20240726093658_b39-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271483","article-title":"Acute coronary syndrome versus acute myocarditis in young adults-value of speckle tracking echocardiography","volume":"17","author":"Wieczorkiewicz","year":"2022","journal-title":"PLoS One"},{"issue":"e207430","key":"key20240726093658_b40-ETM-28-2-12622","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-20-7430","article-title":"Myocarditis mimicking stress-induced (takotsubo) cardiomyopathy","volume":"49","author":"Canan","year":"2022","journal-title":"Tex Heart Inst J"},{"key":"key20240726093658_b41-ETM-28-2-12622","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrcardio.2015.108","article-title":"Viral myocarditis-diagnosis, treatment options, and current controversies","volume":"12","author":"Pollack","year":"2015","journal-title":"Nat Rev Cardiol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T06:38:32Z","timestamp":1721975912000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2024.12622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2024.12622","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"article-number":"333"}}